Title:
OCULAR HYPOTENSIVE LIPIDS
Document Type and Number:
WIPO Patent Application WO2001058866
Kind Code:
A3
Abstract:
Compounds of formula (1), where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF2 alpha 1-ethanolamide, having the formula (I) was discovered to be present in mammalian tissue as a naturally occuring substance, was synthesized in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye, but not acting through the FP receptor through which many ocular hypotensive prostaglandins act.
Inventors:
WOODWARD DAVID F
USANSKY HELEN H
ANDREWS STEVEN W
BURK ROBERT M
CHEN JUNE
KRAUSS ACHIM H P
MADHU CHERUKURY
USANSKY HELEN H
ANDREWS STEVEN W
BURK ROBERT M
CHEN JUNE
KRAUSS ACHIM H P
MADHU CHERUKURY
Application Number:
PCT/US2001/003665
Publication Date:
March 28, 2002
Filing Date:
February 05, 2001
Export Citation:
Assignee:
ALLERGAN SALES INC (US)
International Classes:
A61K9/00; A61P27/02; A61K31/5575; A61P27/06; C07C405/00; (IPC1-7): C07C405/00
Domestic Patent References:
| WO1999025358A1 | 1999-05-27 | |||
| WO1996036599A1 | 1996-11-21 |
Foreign References:
| FR2258372A1 | 1975-08-18 | |||
| JPS5071650A | 1975-06-13 | |||
| GB1439511A | 1976-06-16 |
Other References:
SCHAAF, THOMAS K. ET AL: "Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogs", J. MED. CHEM. (1979), 22(11), 1340-6, XP002184770
WOODWARD, D. F. ET AL: "Neutral replacement of the carboxylic acid group of prostaglandin F2alpha provides a novel series of ocular hypotensive lipids with pharmacological activity distinct from prostanoids.", IOVS, (MARCH 15, 1998) VOL. 39, NO. 4, PP. S420. MEETING INFO.: ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY FORT LAUDERDALE, FLORIDA, USA MAY 10-15, 1998 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY., XP001041773
WOODWARD, D. F. ET AL: "Neutral replacement of the carboxylic acid group of prostaglandin F2alpha provides a novel series of ocular hypotensive lipids with pharmacological activity distinct from prostanoids.", IOVS, (MARCH 15, 1998) VOL. 39, NO. 4, PP. S420. MEETING INFO.: ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY FORT LAUDERDALE, FLORIDA, USA MAY 10-15, 1998 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY., XP001041773
Download PDF:
Previous Patent: PROCESS FOR THE PREPARATION OF 2-HYDROXY-4-METHYLTHIO BUTYRIC ACID ESTERS
Next Patent: NOVEL COMPOUNDS
Next Patent: NOVEL COMPOUNDS